infliximab
janssen
['infliximab', 'danbio', 'imab ']
plenary:
real-world observational study &gt;1500 pts with ia, 1 year retention infliximab biosimilar ct-p13 to gp1111 switch was high. retention was higher in originator-experienced (92vs83%) &amp; low disease activity
nabi h, danbio abs1112 #acr22 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach